For US Healthcare Professionals Only

Indications and Usage Important Safety Information Full Prescribing Information

Access Resources for Your Patient Care

Request the resources you need to be able to support your patients. Choose from the options below. If there is something that would help support your clinical practice but you don’t see it listed, choose the option for a representative. A member of our team will reach out to see how they can help.


    Do you have a need that isn’t listed? We’ll have a representative contact you to see how we can support you and your patients.

    Did you know there is an app, HAE & Me, that your patients can use to track the symptoms of hereditary angioedema (HAE)? It may help you get a more complete picture of their experience and support treatment adherence. Request a video demonstration so you and your staff can see how it works.

    Let us do the printing for you. Request printed patient enrollment forms for your prescriptions of RUCONEST. We will send forms that are in English and Spanish.

    Save yourself and your staff time with templates for appeal letters and letters of medical necessity.

    Ensure that your patients have uninterrupted access to their medication. With the RUCONEST StarterRx Program, patients new to RUCONEST may be eligible for a free trial. For eligible patients in need of more time to confirm coverage, the RUCONEST Bridge to Therapy Program is available to help avoid a gap in therapy.

    Help support patient education. Request self-administration guides that you can provide to patients when you are considering the use of RUCONEST, after you’ve written the prescription, or when you are monitoring safe administration with follow-up teaching.

    With training, your patients may be more capable of confidently self-injecting than you realize. In fact, approximately 85% of patients felt confident with self-administration of RUCONEST (n=601).1

    Request access to a patient-instruction video for use in your clinical practice, and get a jump start on education.

    Streamline billing and claims submission with a guide to commonly used codes related to RUCONEST.

    You have a lot to remember. We’ve created a practical guide to help support you in the diagnosis of HAE.

    Help your patients better understand HAE. These animated videos can help.

    Confirm your contact information

    Please double-check your email, phone number, and address to be sure we have current information.

    *Required field.

    Please see our Privacy Policy and Terms of Use.

    Indications and Usage

    RUCONEST® (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

    Important Safety Information

    RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.

    Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment.

    Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.

    Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.

    The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.

    Before prescribing RUCONEST, please read the full Prescribing Information including the Patient Product Information.

    REFERENCES: 1. Data on file, Pharming Healthcare Inc; 2019.

    Indications and Usage

    RUCONEST® (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

    Important Safety Information

    RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.

    Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment.

    Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.

    Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.

    The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.

    Before prescribing RUCONEST, please read the full Prescribing Information including the Patient Product Information.